Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study

Published:2015-08-20 Issue:10 Volume:17 Page:974-983
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Miyagawa J.¹,Odawara M.²,Takamura T.³,Iwamoto N.⁴,Takita Y.⁴,Imaoka T.⁴

Affiliation:

1. Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine Hyogo College of Medicine Nishinomiya Japan

2. Division of Diabetes, Endocrinology and Metabolism, Department of Diabetes, Endocrinology, Metabolism and Rheumatology Tokyo Medical University Tokyo Japan

3. Department of Comprehensive Metabology Kanazawa University Graduate School of Medical Sciences Kanazawa Japan

4. Eli Lilly Japan K.K Kobe Japan

Funder

Boehringer Ingelheim

Eli Lilly and Company

AstraZeneca

Novartis Pharma

Sanofi

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12534

Reference36 articles.

1. Muscarinic Receptors Control Glucagon-Like Peptide 1 Secretion by Human Endocrine L Cells

2. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

4. Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

5. Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN);Diabetes, Obesity and Metabolism;2024-05-07

2. PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan;Journal of Diabetes Investigation;2024-05-06

3. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression;Diabetes, Obesity and Metabolism;2024-03-20

4. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression;2024-01-30

5. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study;Journal of Diabetes Research;2024-01-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3